ÂÜÀòÂÒÂ×

Keizo Koya has a diverse and extensive work experience in the field of pharmaceutical research and development. Keizo began their career as a Scientist at Fuji Film, where they conducted molecular design and organic synthesis of new chemicals. Keizo then became the Chief Scientist of the first pharmaceutical project at Fuji Film, overseeing the development of new drugs.

Koya later joined the Dana-Farber Cancer Institute as an Invited Researcher, where they played a key role in the research and development of novel anti-cancer drugs. Keizo managed a three-year project between Dana-Farber Cancer Institute and Fuji Film, focusing on anti-cancer screening, pharmacology, pharmacokinetics, toxicology studies, and basic molecular, cellular, and biochemical research.

In 1993, Koya joined FUJIFILM Holdings America Corporation as the Director of Drug Discovery and Development for Fuji ImmunoPharmaceuticals. Keizo managed projects to discover and develop small molecule drugs and genetically engineered immunological proteins. Keizo was also the Head of Pharmaceutical R&D at FUJIFILM America, leading preclinical and clinical research and development of MKT-077, a novel anti-cancer drug.

Koya then moved on to Shionogi & Co., Ltd, where they served as Vice President of R&D for Shionogi Bioresearch in Boston. Keizo led research and development efforts for investigational drugs, focusing on disease target identification, assay development, compound library establishment, high throughput screening, lead optimization, pharmacology, toxicology, pharmacokinetics, and drug metabolism.

In 2002, Koya joined Synta Pharmaceuticals as the Senior Vice President of Drug Development. Keizo was responsible for managing the Chemistry and Pharmaceutical Development departments, overseeing drug discovery and non-clinical development processes. Their role included program management, strategic development program design, pharmaceutical process development, GMP manufacturing, and clinical supply management.

In 2012, Koya founded Strategia Holdings LLC, where they served as the President & CEO. The company collaborates with global partners to advance pharmaceutical R&D projects and streamline the drug development process.

Most recently, Koya founded SOLA Biosciences in 2016 and serves as the CEO and President. The company focuses on improving patient care through innovative bioscience solutions.

Overall, Keizo Koya has held various leadership roles in the pharmaceutical industry, driving research and development efforts and contributing to the discovery and development of novel drugs.

Keizo Koya holds a Doctor of Philosophy - PhD degree in Organic Chemistry from Kyushu University. No specific start or end year for this educational experience is provided.